Role of protein phosphatase 2A in Alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 6, 2011, Pages 623-632

  Rudrabhatla, P ^a   Pant, H C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Alzheimer's disease; Neurofilaments; Pin1; Protein dephosphorylation; Protein kinases and phosphatases; Protein phosphatase 2a; Tau

Indexed keywords

CALCINEURIN; CANTHARIDIN; GLYCOGEN SYNTHASE KINASE 3; MICROCYSTIN LR; NODULARIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN; TAUTOMYCIN;

ALZHEIMER DISEASE; DEMENTIA; DOWN REGULATION; MICROCYSTIS AERUGINOSA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEUROFIBRILLARY TANGLES; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 80051713257     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796717168     Document Type: Review

References (123)

1. Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B. Histopathological criteria for progressive dementia disorders: clinicalpathological correlation and classification by multivariate data analysis. Acta Neuropathol 74: 209-225 (1987).
2. Alonso AD, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated Tau sequesters normal Tau into tangles of filaments and disassembles microtubules. Nat Med 2: 783-787 (1996).
3. Alonso AD, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated Tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91: 5562-5566 (1994).
4. Yamasaki H, Itakura C, Mizutani M. Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathol 82: 427-434 (1991).
5. Mata M, Kupina M, Fink DJ. Phosphorylation-dependent neurofilament epitopes are reduced in nodes of Ranvier. Neurocytology 21: 199-210 (1992).
6. O'Hara O, Gahara Y, Miyake T, Teraoka H, Kitamura T. Neurofilament deficiency in quail caused by nonsense mutation in neurofilament- L gene. J Cell Biol 121: 387-395 (1993).
7. DeWaegh SM, Lee VMY, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 68: 451-463 (1992).
8. Eyer J, Peterson A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilamentbeta- galactosidase fusion protein. Neuron 12: 389-405 (1994).
9. Goldstein ME, Sternberger NH, Sternberger LA. Phosphorylation protects neurofilaments againsts proteolysis. J Neuroimmunol 14: 149-160 (1987).
10. Pant HC. Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain. Biochem J 256: 665-668 (1988).
11. Krinks MH, Klee CB, Pant HC, Gainer H. Identification and quantification of calcium binding proteins in squid axoplasm. J Neurosci 8: 2172-2182 (1988).
12. Sternberger NH, Sternberger LA, Ulrich, J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci USA 82: 4274-4276 (1985).
13. Cook LC, Steinberger NH, Steinberger LA, Casonva MF, Struble RG. Phosphorylated neurofilament antigens in neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 45: 56-64 (1986).
14. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFeria FM. Tripletransgenic model of Alzheimer's disease with plaques and tangles: Intracellular amyloid-beta and synaptic dysfunction. Neuron 39, 409-421 (2003).
15. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14: 6-16 (2000).
16. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, et al. Protein tyrosine phosphatases in the human genome. Cell 117: 699-711 (2004).
17. Barford D. Molecular mechanisms of the protein serine/threonine phosphatases. Trends Biochem Sci 21:407-412 (1996).
18. Gallego M, Virshup DM. Protein serine/threonine phosphatases: life, death, and sleeping. Curr Opin Cell Biol 17: 197-202 (2005).
19. Barford D, Das AK, Egloff MP. The structure and mechanism of protein phosphatases: Insights into catalysis and regulation. Ann Review Biophysics Biomolecular Structure 27: 133-164 (1998).
20. Turowski P, Favre B, Campbell KS, Lamb NJC, Hemmings BA. Modulation of the enzymatic properties of protein phosphatase 2A catalytic subunit by the recombinant 65kDa regulatory subunit PR65-alpha. Eur J Biochem 248: 200-208 (1997).
21. Mayer-Jaekel RE, Hemmings BA. Protein phosphatase 2A is a "menage a trois ". Trends Cell Biol 4: 287-291 (1994).
22. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 58: 453-508 (1989).
23. Xing YN, Xu YH, Chen Y, Jeffrey PD, Chao Y, Lin Z, et al. Structure of proteinphosphatase2A core enzyme bound to tumorinducing toxins. Cell 127: 341-353 (2006).
24. Cho US, Xu WQ. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445(1): 53-57 (2006).
25. Cohen PT, Brewis ND, Hughes V, Mann DJ. Protein serine/ threonine phosphatases; an expanding family. FEBS Lett 268(2): 355-359 (1990).
26. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439 (2001).
27. Arino J, Woon CW, Brautigan DL, Miller TB Jr, Johnson GL. Human liver phosphatase 2A: cDNA and amino acid sequence of two catalytic subunit isotypes. Proc Natl Acad Sci USA 85(12): 4252-4256 (1988).
28. Green DD, Yang SI, Mumby MC. Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc Natl Acad Sci USA 84(14): 4880-4 (1987).
29. Hemmings BA, Adams-Pearson C, Maurer F, Müller P, Goris J, Merlevede W, et al. alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry 29(13): 3166-3173. (1990)
30. Xing Y, Xu Y, Chen Y, Jeffrey PD, Chao Y, Lin Z, et al. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127(2): 341-353 (2006).
31. MacKintosh C, Klumpp S. Tautomycin from the bacterium Streptomyces verticillatus. Another potent and specific inhibitor of protein phosphatases 1 and 2A. FEBS Lett 277: 137-140 (1990)
32. Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 159: 871-877 (1989).
33. Honkanen RE, Zwiller J, Moore RE, Daily SL, Khatra BS, Dukelow M, et al. Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. J Biol Chem 265: 19401-19404 (1990).
34. Honkanen RE, Dukelow M, Zwiller J, Moore RE, Khatra BS, Boynton AL. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases. Cell Pharmacol 40: 577-583 (1991).
35. Li YM, Casida JE. Cantharidin binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 89: 11867-11870 (1992).
36. Li M, Guo H, Damuni Z. Urification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34: 1988-1996 (1995).
37. Li M, Makkinje A, Damuni Z. Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 35: 6998-7002 (1996).
38. Tsujio I, Zaidi T, Xu J, Kotula L, Grundke-Iqbal, Iqbal K. Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated Tau. FEBS Lett 579: 363-372. (2005)
39. Ulitzur N, Rancano C, Pfeffer SR. Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins. J Biol Chem 272: 30577-30582 (1997).
40. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosvela G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol 12: 3346-3355 (1992).
41. Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol 166: 1761-1771 (2005).
42. Chen S, Grundke-Iqbal I, Iqbal K. I1 PP2A and I2 PP2A affect Tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. Alzheimers Dement 2: S471(2006).
43. Chen S, Li B, Grundke-Iqbal I, Iqbal K. I1PP2A affects Tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem 283:10513-10521 (2008).
44. Walaas SI, Greengard P. Protein phosphorylation and neuronal function. Pharmacol Rev 43: 299-349 (1991).
45. Nishi A, Snyder GL, Nairn AC, Greengard P. Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons. J Neurochem 72: 2015-2021 (1999).
46. Chernoff J, Li HC, Cheng YSE, Chen LB. Characterization of a phosphotyrosyl protein phosphatase activity associated with a phosphoseryl protein phosphatase of Mr = 95,000 from bovine heart. J Biol Chem 258: 7852-7857 (1983).
47. Silberman SR, Speth M, Nemani R, Ganapathi MK, Dombradi V, Paris H, et al. Isolation and characterization of rabbit skeletal muscle protein phosphatases C-I and C-II. J Biol Chem 259: 2913-2922 (1984).
48. Hermann J, Cayla X, Dumortier K, Goris J, Ozon R, Merlevede W. Polycationstimulated (PCSL) protein phosphatase from Xenopus laevis oocytes. ATP-mediated regulation of alkaline phosphatase activity. Eur J Biochem 173: 17-25 (1988).
49. Goris J, Pallen CJ, Parker PJ, Hermann J, Waterfield MD, Merlevede, W. Conversion of a phosphoseryl/threonyl phosphatase into a phosphotyrosyl phosphatase. Biochem J 256: 1029-1034 (1988).
50. Jessus C, Goris J, Cayla X, Hermann J, Hendrix P, Ozon R, et al. Tubulin and MAP2 regulate the PCSL phosphatase activity. A possible new role for microtubular proteins. Eur J Biochem 180: 15-22 (1989).
51. Cayla X, Goris J, Hermann J, Hendrix P, Ozon R, Merlevede W. Isolation and characterization of a tyrosyl phosphatase activator from rabbit skeletal muscle and Xenopus laevis oocytes. Biochemistry 29: 658-667 (1990).
52. Van Hoof C, Cayla X, Bosch M, Merlevede W, Goris J. The phosphotyrosyl phosphatase activator of protein phosphatase 2A. A novel purification method, immunological and enzymic characterization. Eur J Biochem 226: 899-907 (1994).
53. Van Hoof C, Janssens V, Dinishiotu A, Merlevede W, Goris J. Functional analysis of conserved domains in the phosphotyrosyl phosphatase activator. Molecular cloning of the homologues from Drosophila melanogaster and Saccharomyces cerevisiae. Biochemistry 37: 12899-12908 (1998).
54. Janssens V, Van Hoof C, Merlevede W, Goris, J. PTPA regulating PP2A as a dual specificity phosphatase. Methods Mol Biol 93: 103-115 (1998).
55. Cayla X, Van Hoof C, Bosch M, Waelkens E, Vandekerckhove J, Peeters B, et al. Molecular cloning, expression, and characterization of PTPA, a protein that activates the tyrosyl phosphatase activity of protein phosphatase 2A. J Biol Chem 269: 15668-15675 (1994).
56. Leulliot N, Vicentini G, Jordens J, Quevillon-Cheruel S, Schiltz M, Barford D, et al. Crystal structure of the PP2A phosphatase activator: implications for its PP2A-specific PPIase activity. Mol Cell 23: 413-424. (2006).
57. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22: 1942 (2005).
58. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of Tau in rat forebrain. FEBS Lett 485: 87-93 (2000).
59. Gong CX, Wegiel J, Lidsky T, Zuck L, Avila J, Wisniewski HM, et al. Regulation of phosphorylation of neuronal microtubuleassociated proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain. Brain Res 853: 299-309 (2000).
60. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of Tau in transgenic mice. J Biol Chem 276: 38193-38200 (2001).
61. Burack MA, Halpain S. Site-specific regulation of alzheimer-like Tau phosphorylation in living neurons. Neuroscience 72 167-184 (1996).
62. Johnson GV. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis 9: 243-250 (2006).
63. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki N, Yoshida H, Titani K, et al. Proline-directed and non-proline-directed phosphorylation of PHF-Tau. J Biol Chem 270: 823-829 (1995).
64. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated Tau (paired helical filament-Tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71: 2465-2476 (1998).
65. Johnson GV, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. J Alzheimers Dis 1: 329-351(1999).
66. Singh TJ, Grundke-Iqbal I, McDonald B, Iqbal K. Comparison of the phosphorylation of microtubule-associated protein Tau by nonproline dependent protein kinases. Mol Cell Biochem 131:181-189 (1994).
67. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, Tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:27-39 (2001).
68. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkade, Gong CX, et al. Tau pathology in Alzheimer disease and other Tauopathies. Biochim Biophys Acta. 1739:198-210 (2005).
69. Pei JJ, Braak E, Braak H, Grunke-Iqbal I, Iqbal K, Winblad B et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol. 58:1010-1019 (1999).
70. Pei JJ, Grundke-Iqbal I, Iqbal K, Boqdanovic N, Winblad B, Cowburn RF. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797:267-277 (1998).
71. Noble W, Olm V, Takata K, Casey E, Marry O, Meyerson J, et al. Cdk5 is a key factor in Tau aggregation and tangle formation in vivo. Neuron 38:555-565 (2003).
72. Kusakawa G, Saito T, Onuki R, Ishiquro K, Kishimoto T, Hisanage S. Calpain-dependent proteolytic cleavage of the p35 cyclindependent kinase 5 activator to p25. J Biol Chem. 275:17166-17172 (2000).
73. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40: 471-483 (2003).
74. Ledesma MD, Correas I, Avila J, Diaz-Nido J. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of Tau protein in Alzheimer's disease. FEBS Lett 308: 218-224 (1992).
75. Roder HM, Eden PA, Ingram VM. Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Commun 193: 639-647 (1993).
76. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol. 163:845-858 (2003).
77. Drewes G, Lichtenberg-Kraag B, Doring F, et al. Mitogen activated protein (MAP) kinase transforms Tau protein into an Alzheimer- like state. EMBO J. 11:2131-2138 (1992).
78. An WL, Cowburn RF, Li L, Alafuzzoff I, Iqbal K, Iqbal IG, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol. 163:591-607 (2003).
79. Singh TJ, Wang JZ, Novak M, Kontzekova E, Grunde-Iqbal I, Iqbal K. Calcium/calmodulin-dependent protein kinase II phosphorylates Tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett. 387:145-148 (1996).
80. Scott CW, Spreen RC, Herman JL, Chow FP, Davison MD, Young J, et al. Phosphorylation of recombinant Tau by cAMPdependent protein kinase Identification of phosphorylation sites and effect on microtubule assembly. J Biol Chem. 268:1166-1173 (1993).
81. Oliver CJ, Shenolikar S. Physiologic importance of protein phosphatase inhibitors, Front Biosci 3: 961-972 (1998).
82. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, et al. Molecular interactions among protein phosphatase 2A, tau, and microtubules: Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 274: 25490-25498 (1999).
83. Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides Tau protein kinase I/glycogen synthase kinase 3β and cyclindependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 276: 34298-34306 (2001).
84. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of Tau and associated neurodegeneration. FEBS Lett 566: 261-269 (2004).
85. Chin SS, Liem RK. Transfected rat high-molecular-weight neurofilament (NF-H) coassembles with vimentin in a predominantly nonphosphorylated form. J Neurosci 10: 3714-3726 (1990).
86. Nixon RA, Sihag RK. Neurofilament phosphorylation: a new look at regulation and function. Trends Neurosci 14: 501-506 (1991).
87. HC Pant, Veeranna, P Grant. Regulation of axonal neurofilament phosphorylation, Curr. Top. Cell Regul 36133-150 (2000).
88. Sihag RK, M Inagaki, T Yamaguchi, TB Shea, HC Pant. Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments. Exp Cell Res 313: 2098-2109 (2007).
89. Vogelsberg-Ragaglia VT, Schuck JQ, Trojanowski, VM Lee. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168: 402-412 (2001).
90. Sontag EA, Luangpirom C, Hladik I, Mudrak E, Ogris S, Speciale, et al. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63: 287-301 (2004).
91. Gong X, TJ Singh, I Grundke-Iqbal, K Iqbal. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61: 921-927 (1993).
92. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal. Phosphatase activity toward abnormally phosphorylated Tau: decrease in Alzheimer disease brain. J Neurochem 65: 732-738 (1995).
93. Gong CX, T Lidsky, J Wegiel, L Zuck, I Grundke-Iqbal, K Iqbal. Phosphorylation of microtubule-associated protein Tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 275: 5535-5544 (2000).
94. Sim ATR. The regulation and function of protein phosphatases in the brain. Mol Neurobiol 5: 229-246 (1991).
95. Guru SC, Shetty KT, Shankar SK. Effect of chronic ethanol ingestion on phosphate content of NF proteins and NF associated protein phosphatase in rat spinal cord. Neurochem Res 16: 1193-1197 (1991).
96. Shetty KT, Veeranna, Guru SC. Effect of chronic ethanol ingestion on phosphate content of neurofilament proteins and neurofilament associated protein phosphatase in rat spinal cord. Neurosci Lett 137: 83-86 (1992).
97. Nixon RA, Lewis SE, Marotta CA. Posttranslational modification of neurofilament proteins by phosphate during axoplasmic transport in retinal ganglion cell neurons. J Neurosci 7: 1145-1158 (1987).
98. De Waegh SM, Lee VM, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber and slow axonal transport by mylenating Schwann cells. Cell 68: 451-463 (1992).
99. Mata M, Kupina N, Fink DJ. Phosphorylation dependent neurofilament epitopes are reduced at the node of Ranvier. J Neurocytol 21: 199-210 (1992).
100. Veeranna, Shetty KT, Link WT, Jaffe H, Wang J, Pant HC. Neuronal cyclin-dependent kinase-5 phosphorylation sites in neurofilament protein (NF-H) are dephosphorylated by protein phosphatase 2A. J Neurochem 64: 2681-2690 (1995).
101. Dashiell SM, Tanner SL, Pant HC, Quarles RH. Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J Neurochem 81: 1263-1272 (2002).
102. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168: 402-412 (2001).
103. Strack S, Westphal RS, Colbran RJ, Ebner FF, Wadzinski BE. Protein serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Brain Res Mol Brain Res 49: 15-28 (1997).
104. Krinks MH, Klee CB, Pant HC, Gainer H. Identification and quantification of calcium-binding proteins in squid axoplasm. J Neurosci 8: 2172-2182 (1988).
105. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of Tau phosphorylation. Eur J Neurosci 22: 1942-1950 (2005).
106. ] Veeranna, Yang DS, Lee JH, Vinod KY, Stavrides P, Amin ND, et al. Declining phosphatases underlie aging-related hyperphosphorylation of neurofilaments. Neurobiol Aging 109 (2009).
107. Tanimukai H, Grundke-Iqbal I, Iqbal, K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol 166: 1761-1771 (2005).
108. Vitek MP, Christensen DJ, Wilcock D, Oddo J, Gharkholonarehe N, Ohkubo, et al. Novel mechanism where ApoE mimetics activate PP2A activity and reduce Alzheimer's pathology in three different transgenic models. Alzheimer's Demen.: J Alzheimer's Assoc 5 P111 (2009).
109. Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signaling and disease. Nat Rev Mol Cell Biol 8: 904-916 (2007).
110. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, et al. Sequence-specific and phosphorylationdependent proline isomerization: a potential mitotic regulatory mechanism. Science 278: 1957-1960 (1997).
111. Rudrabhatla P, Zheng YL, Amin ND, Kesavapany S, Albers W, Pant HC. Pin1dependent prolyl isomerization modulates the stressinduced phosphorylation of high molecular weight neurofilament protein. J Biol Chem 283: 26737-26747 (2008).
112. Kesavapany S, Patel V, Zheng YL, Pareek TK, Bjelogrlic M, Albers W, et al. Inhibition of Pin1 reduces glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. Mol Biol Cell 18: 3645-3655 (2007).
113. Lonati E, Masserini M, Bulbarelli A. (2011) Pin1: a new outlook in Alzheimer Disease. Current Alzheimeŕs Research. Special thematic Issue Tau protein and Alzheimeŕs disease. New paradigms and future challenges Curr Alzheimers Res 8(6): 615-622 (2011).
114. Ryo A, Togo T, Nakai T, Hirai A, Nishi M, Yamaguchi A, et al. The prolyl-isomerase Pin1 accumulates in the Lewy bodies of Parkinson's disease and facilitates the formation of alpha-synuclein inclusions. J Biol Chem 281: 4117-4125 (2006).
115. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated Tau protein. Nature 399: 784-788 (1999).
116. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F, et al. Role of the prolyl isomerase Pin1 in protecting against agedependent neurodegeneration. Proc Natl Acad Sci USA 99: 1335-1340 (2002).
117. Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, Sun A, et al. Pin1 has opposite effects on wild-type and P301L Tau stability and Tauopathy. J Clin Invest 118: 1877-1889 (2008).
118. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Slegtenhorst MV, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) Tau protein. Nat Genet 25: 402-405 (2000).
119. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 293: 1487-1491 (2001).
120. Xu YX, Hirose Y, Zhou XZ, Lu KP, Manley JL. Pin1 modulates the structure and function of human RNA polymerase II. Genes Dev 17: 2765-2776 (2003).
121. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by betaamyloid(1-40). Brain Res 958: 210-221 (2002).
122. Chohan MO, Khatoon S, Grundke-Iqbal I, Iqbal K. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 580: 3973-3979 (2006).
123. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566: 261-269 (2004).